“This is one of the most important trials of cholesterol-lowering since the first statin trial, published 20 years ago. Our results suggest this new, extremely potent class of drug can cut cholesterol dramatically, which could provide great benefit for a lot of people at risk of heart disease and stroke,” Prof Peter Sever, from Imperial College London – which led the UK branch of the study, said. As about the action mechanism of the new drug, it was explained: “A promising new approach is blocking the action of PCSK9, a molecule which reduces the breakdown of LDL-cholesterol in the liver. Creating new treatments which use this approach could prove life-saving for patients with high cholesterol and those who can’t tolerate statins.” The study was published in the New England Journal of Medicine. Evolocumab (under trade name Repatha) is a monoclonal antibody designed for the treatment of hyperlipidemia. It’s cost in 2015 was about $14,300 USD per year.